Positron emission tomography as a method for measuring drug delivery to tumors in vivo: The example of [11C]docetaxel

Frontiers in Oncology

Volumn 3 AUG, Issue , 2013, Pages

  Van der Veldt, Astrid A M ^a   Smit, Egbert F ^a   Lammertsma, Adriaan A ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

11C docetaxel; Drug delivery; Lung cancer; Positron emission tomography; Radiolabeled anticancer drugs; Tumors

Indexed keywords

3 DEOXY 3 [18F] FLUOROTHYMIDINE; [11C] DOCETAXEL; [11C] ERLOTINIB; [11C] SORAFENIB; [11C] TEMOZOLOMIDE; [18F] 5 FLUOROURACIL; [18F] FLUOROAZOMYCINARABINOFURANOSIDE; [18F] FLUOROMISONIDAZOLE; [18F] FLUOROTAMOXIFEN; [89ZR] BEVACIZUMAB; [89ZR] CETUXIMAB; [89ZR] TRASTUZUMAB; BEVACIZUMAB; CORTICOSTEROID; DEXAMETHASONE; DOCETAXEL; FLUORINE 18; N [11C] METHYLIMATINIB; OXYGEN 15; UNCLASSIFIED DRUG; VASCULOTROPIN;

ARTICLE; BREAST CANCER; CLINICAL PRACTICE; COMPUTER ASSISTED TOMOGRAPHY; DRUG DELIVERY SYSTEM; DRUG TUMOR LEVEL; HEAD AND NECK CANCER; HUMAN; ISOTOPE LABELING; LUNG CANCER; LUNG NON SMALL CELL CANCER; NEOPLASM; NONHUMAN; ONCOLOGY; POSITRON EMISSION TOMOGRAPHY; PROSTATE CANCER; STOMACH ADENOCARCINOMA; TREATMENT PLANNING; TUMOR GROWTH; TUMOR VOLUME;

EID: 84891139124     PISSN: None     EISSN: 2234943X     Source Type: Journal    
DOI: 10.3389/fonc.2013.00208     Document Type: Article

References (38)

1. Gambhir SS. Molecular imaging of cancer with positron emission tomography. Nat Rev Cancer (2002) 2:683-93. doi:10.1038/nrc882
2. Surti S, Kuhn A, Werner ME, Perkins AE, Kolthammer J, Karp JS. Performance of Philips Gemini TF PET/CT scanner with special consideration for its time-of-flight imaging capabilities. J Nucl Med (2007) 48:471-80.
3. Gunn RN, Gunn SR, Cunningham VJ. Positron emission tomography compartmental models. J Cereb Blood Flow Metab (2001) 21:635-52. doi:10.1097/00004647-200106000-00002
4. Boellaard R, van Lingen A, van Balen SC, Hoving BG, Lammertsma AA. Characteristics of a new fully programmable blood sampling device for monitoring blood radioactivity during PET. Eur J Nucl Med (2001) 28:81-9. doi:10.1007/s002590000405
5. Warburg O. On the origin of cancer cells. Science (1956) 123:309-14. doi:10.1126/science.123.3191.309
6. Shields AF, Grierson JR, Dohmen BM, Machulla HJ, Stayanoff JC, Lawhorn-Crews JM, et al. Imaging proliferation in vivo with [F-18]FLT and positron emission tomography. Nat Med (1998) 4:1334-6. doi:10.1038/3337
7. van der Veldt AA, Hendrikse NH, Harms H, Comans EF, Posmus PE, Smit EF, et al. Quantitative parametric perfusion images using oxygen-15 labeled water and a clinical PET-CT scanner: test-retest variability in lung cancer. J Nucl Med (2010) 51:1684-90. doi:10.2967/jnumed.110.079137
8. Sorger D, Patt M, Kumar P, Wiebe LI, Barthel H, Seese A, et al. [18F]Fluoroazomycinarabinofuranoside (18FAZA) and [18F]Fluoromisonidazole (18FMISO): a comparative study of their selective uptake in hypoxic cells and PET imaging in experimental rat tumors. Nucl Med Biol (2003) 30:317-26. doi:10.1016/S0969-8051(02)00442-0
9. Dimitrakopoulou-Strauss A, Strauss LG, Schlag P, Hohenberger P, Mohler M, Oberdorfer F, et al. Fluorine-18-fluorouracil to predict therapy response in liver metastases from colorectal carcinoma. J Nucl Med (1998) 39:1197-202.
10. Moehler M, Dimitrakopoulou-Strauss A, Gutzler F, Raeth U, Strauss LG, Stremmel W. 18F-labeled fluorouracil positron emission tomography and the prognoses of colorectal carcinoma patients with metastases to the liver treated with 5-fluorouracil. Cancer (1998) 83:245-53. doi:10.1002/(SICI)1097-0142(19980715)83:2<245::AID-CNCR7>3.0.CO;2-P
11. Inoue T, Kim EE, Wallace S, Yang DJ, Wong FC, Bassa P, et al. Positron emission tomography using [18F]fluorotamoxifen to evaluate therapeutic responses in patients with breast cancer: preliminary study. Cancer Biother Radiopharm (1996) 11:235-45. doi:10.1089/cbr.1996.11.235
12. van der Veldt AA, Lubberink M, Greuter HN, Comans EF, Herder GJ, Yaqub M, et al. Absolute quantification of [11C]docetaxel kinetics in lung cancer patients using positron emission tomography. Clin Cancer Res (2011) 17:4814-24. doi:10.1158/1078-0432.CCR-10-2933
13. Slobbe P, Poot AJ, Windhorst AD, van Dongen GA. PET imaging with small-molecule tyrosine kinase inhibitors: TKI-PET. Drug Discov Today (2012) 17:1175-87. doi:10.1016/j.drudis
14. van der Veldt AA, Luurtsema G, Lubberink M, Lammertsma AA, Hendrikse NH. Individualized treatment planning in oncology: role of PET and radiolabelled anticancer drugs in predicting tumour resistance. Curr Pharm Des (2008) 14:2914-31. doi:10.2174/138161208786404344
15. Bahce I, Smit EF, Lubberink M, van der Veldt AA, Yaqub M, Windhorst AD, et al. Development of [11C]erlotinib positron emission tomography for in vivo evaluation of EGF receptor mutational status. Clin Cancer Res (2013) 19:183-93. doi:10.1158/1078-0432.CCR-12-0289
16. Kil KE, Ding YS, Lin KS, Alexoff D, Kim SW, Shea C, et al. Synthesis and positron emission tomography studies of carbon-11-labeled imatinib (Gleevec). Nucl Med Biol (2007) 34:153-63. doi:10.1016/j.nucmedbio.2006.11.004
17. Saleem A, Brown GD, Brady F, Aboagye EO, Osman S, Luthra SK, et al. Metabolic activation of temozolomide measured in vivo using positron emission tomography. Cancer Res (2003) 63:2409-15.
18. Cai W, Chen K, He L, Cao Q, Koong A, Chen X. Quantitative PET of EGFR expression in xenograft-bearing mice using 64Cu-labeled cetuximab, a chimeric anti-EGFR monoclonal antibody. Eur J Nucl Med Mol Imaging (2007) 34:850-8. doi:10.1007/s00259-006-0361-6
19. Verel I, Visser GW, Boerman OC, van Eerd JE, Finn R, Boellaard R, et al. Long-lived positron emitters zirconium-89 and iodine-124 for scouting of therapeutic radioimmunoconjugates with PET. Cancer Biother Radiopharm (2003) 18:655-61. doi:10.1089/108497803322287745
20. Nagengast WB, de Vries EG, Hospers GA, Mulder NH, de Jong JR, Hollema H, et al. In vivo VEGF imaging with radiolabeled bevacizumab in a human ovarian tumor xenograft. J Nucl Med (2007) 48:1313-9. doi:10.2967/jnumed.107.041301
21. Montero A, Fossella F, Hortobagyi G, Valero V. Docetaxel for treatment of solid tumours: a systematic review of clinical data. Lancet Oncol (2005) 6:229-39. doi:10.1016/S1470-2045(05)70094-2
22. van Tilburg EW, Franssen EJ, van der Hoeven JJ, van der Meij M, Elshove D, Lammertsma AA, et al. Radiosynthesis of [11C]docetaxel. J Label Compd Radiopharm (2004) 47:763-77. doi:10.1002/jlcr.861
23. van Tilburg EW, Mooijer MP, Brinkhorst J, van der Meij M, Windhorst AD. Improved and semi-automated GMP-compliant radiosynthesis of [11C]docetaxel. Appl Radiat Isot (2008) 66:1414-8. doi:10.1016/j.apradiso.2008.02.076
24. van der Veldt AA, Lammertsma AA, Hendrikse NH. [11C] docetaxel and positron emission tomography for noninvasive measurements of docetaxel kinetics. Clin Cancer Res (2007) 13:7522-3. doi:10.1158/1078-0432.CCR-07-1626
25. van der Veldt AA, Hendrikse NH, Smit EF, Mooijer PJ, Rynders AY, Gerristen WR, et al. Biodistribution and radiation dosimetry of 11C-labeled docetaxel in cancer patients. Eur J Nucl Med (2010) 37:1950-8. doi:10.1007/s00259-010-1489-y
26. Latreille J, Gelmon KA, Hirsh V, Laberge F, Maksymiuk AW, Shepherd FA, et al. Phase II trial of docetaxel with dexamethasone premedication in patients with advanced non-small cell lung cancer: the Canadian experience. Invest New Drugs (1999) 16:265-70. doi:10.1023/A:1006126505910
27. Piccart MJ, Klijn J, Paridaens R, Nooij M, Mauriac L, Coleman R, et al. Corticosteroids significantly delay the onset of docetaxel-induced fluid retention: final results of a randomized study of the European Organization for Research and Treatment of Cancer Investigational Drug Branch for Breast Cancer. J Clin Oncol (1997) 15:3149-55.
28. van der Veldt AA, Lubberink M, Mathijssen RH, Loos W, Herder GJ, Greuter HN, et al. Toward prediction of efficacy of chemotherapy: a proof of concept study in lung cancer patients using [11C]docetaxel and positron emission tomography. Clin Cancer Res (2013) 19:4163-73. doi:10.1158/1078-0432.CCR-12-3779
29. Harte RJ, Matthews JC, O'Reilly SM, Tilsley DW, Osman S, Brown G, et al. Tumor, normal tissue, and plasma pharmacokinetic studies of fluorouracil biomodulation with N-phosphonacetyl-L-aspartate, folinic acid, and interferon alfa. J Clin Oncol (1999) 17:1580-8.
30. Propper DJ, de Bono J, Saleem A, Ellard S, Flanagan E, Paul J, et al. Use of positron emission tomography in pharmacokinetic studies to investigate therapeutic advantage in a phase I study of 120-hour intravenous infusion XR5000. J Clin Oncol (2003) 21:203-10. doi:10.1200/JCO.2003.02.008
31. Saleem A, Harte RJ, Matthews JC, Osman S, Brady F, Luthra SK, et al. Pharmacokinetic evaluation of N-[2-(dimethylamino)ethyl]acridine-4-carboxamide in patients by positron emission tomography. J Clin Oncol (2001) 19:1421-9.
32. Solbach C, Patt M, Reimold M, Blocher A, Dohmen BM, Bares R, et al. Vinblastine syntheses and preliminary imaging in cancer patients. J Pharm Pharm Sci (2007) 10:266s-76.
33. van der Veldt AA, Lubberink M, Bahce I, Walraven M, de Boer MP, Greuter HN, et al. Rapid decrease in delivery of chemotherapy to tumors after anti-VEGF therapy: implications for scheduling of anti-angiogenic drugs. Cancer Cell (2012) 21:82-91. doi:10.1016/j.ccr.2011.11.023
34. Sandler A, Gray R, Perry MC, Brahmer J, Schiller JH, Dowlati A, et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small cell lung cancer. N Engl J Med (2006) 355:2542-50. doi:10.1056/NEJMoa061884
35. Jain RK. Normalizing tumor vasculature with anti-angiogenic therapy: a new paradigm for combination therapy. Nat Med (2001) 7:987-9. doi:10.1038/89889
36. Casanovas O. Cancer: limitations of therapies exposed. Nature (2012) 484:44-6. doi:10.1038/484044a
37. van der Veldt AA, Lammertsma AA, Smit EF. Scheduling of anticancer drugs: timing may be everything. Cell Cycle (2012) 11:4339-43. doi:10.4161/cc.22187
38. van der Veldt AA, Smit EF. Bevacizumab in neoadjuvant treatment for breast cancer. N Engl J Med (2012) 366:1637-40. doi:10.1056/NEJMc1202229